🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million new cases annually. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the context of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

According to results released by a major medical journal, the new drug cured more than 90% of cases of the STI. This establishes an comparable level with the typical regimen, which involves a dual-drug approach. The study enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Doctors treating patients have expressed hope. Having a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is deemed essential to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea around the world.